AHA 2024 - Daniel Judge discusses the findings from the ATTRibute-CM-OLE trial, the open-label extension study of ATTRibute-CM with the oral TTR stabilizer acoramidis in patients with ATTR-CM.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
AHA 2024 - Daniel Judge discusses the findings from the ATTRibute-CM-OLE trial, the open-label extension study of ATTRibute-CM with the oral TTR stabilizer acoramidis in patients with ATTR-CM.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Daniel Judge, MD is a professor of medicine in cardiology at Medical University of South Carolina (MUSC) in Charleston, SC, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of ATTRibute-CM-OLE have been published in Circulation
Release date: 18 November 2024
AHA 2024 - Daniel Judge discusses the findings from the ATTRibute-CM-OLE trial, the open-label extension study of ATTRibute-CM with the oral TTR stabilizer acoramidis in patients with ATTR-CM.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Daniel Judge, MD is a professor of medicine in cardiology at Medical University of South Carolina (MUSC) in Charleston, SC, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of ATTRibute-CM-OLE have been published in Circulation
Release date: 18 November 2024
Stay current with the best on medical education
